Table 1.

Summary of cases of haematological adverse effects following rituximab

Pt#	Author (year)	Infusion	G	Age	Haematological disease	Splenomegaly	Preplatelets	Preleukocytes	Pre-Hb	Pre-D-dimer	Pre-fib	Pre-INR	Pre-LDH	Rituximab dose	Hours to ADR	Postplatelets	Postleukocytes	Post-Hb	Post-D-dimer	Post-fib	Post-INR	Post-LDH	CRS	Intravascular fibrinolysis	Shistocytes
1	Rigamonti (2001)	1	F	60	LPL	Yes	86 000	1100	9.7	NS	NS	NS	NS	375 mg/m2	5	7000	1100	9.7	Normal	Normal	Normal	2×up	Yes	No	NS
2	Shah (2004)	1	M	57	MCL	Yes	151 000	10 800	9.4	NS	NS	NS	NS	375 mg/m2	24	8000	6000	7.7	NS	NS	NS	NS	Yes	NS	NS
3	Pamuk (2005)	1	M	75	B-cell PLL	Yes	92 000	160 000	7.7	NS	NS	NS	NS	375 mg/m2	4	7000	12 000	7.4	NS	NS	NS	NS	NS	NS	NS
4	Otrock (2005)	1	M	41	HCL	Yes	85 000	2800	9.5	NS	NS	NS	NS	375 mg/m2	24	7000	NS	NS	NS	NS	NS	NS	Yes	NS	NS
5	Otrock (2005)	1	M	64	MCL	NS	90 000	90 200	10.5	NS	NS	NS	NS	375 mg/m2	24	10 000	NS	NS	NS	NS	NS	NS	Yes	NS	NS
6	Thachil (2006)	1	M	44	HCL	NS	31 000	1400	9.4	NS	NS	NS	NS	NS	5	6000	NS	NS	33 020 ng/ml	410	1.2	NS	No	Yes	NS
7	Rosado (2007)	1	M	64	MCL	NS	175 000	NS	NS	NS	NS	NS	NS	375 mg/m2	24	22 000	NS	NS	NS	NS	NS	NS	NS	NS	No
7	Rosada (2007)	2	M	64	MCL	NS	135 000	NS	NS	NS	NS	NS	NS	375 mg/m2	18	11 000	NS	NS	NS	NS	NS	NS	NS	NS	No
8	Yi (2009)	1	M	58	MCL-BV	Yes	132 000	NS	NS	NS	NS	NS	994	375 mg/m2	24	24 000	NS	NS	Normal	Normal	Normal	3018	Yes	No	NS
8	Yi (2009)	2	M	58	MCL-BV	Yes	139 000	NS	NS	NS	NS	NS	NS	375 mg/m2	8	48 000	NS	NS	NS	NS	NS	NS	Yes	NS	NS
9	Dhand (2008)	1	M	84	MCL	NS	121 000	NS	NS	NS	NS	NS	NS	375 mg/m2	24	15 000	NS	NS	NS	NS	NS	NS	No	NS	NS
10	Ram (2009)	1	F	71	MCL	NS	63 000	80 000	10.5	NS	NS	NS	NS	375 mg/m2	18	10 000	1000	NS	NS	NS	NS	NS	Yes	No	No
11	Kotsianidis (2009)	1	M	74	Atypical HCL	Yes	127 000	49 700	13.7	NS	NS	NS	NS	375 mg/m2	24	21 000	28 000	NS	15 470 mg/dL	127	2.43	2×ULN	No	Yes	No
12	Adiyodi (2010)	1	F	83	HCL	Yes	74 000	NS	NS	NS	NS	NS	NS	NS	12	22 000	NS	NS	High	Normal	Normal	NS	Yes	NS	NS
13	Adiyodi (2010)	1	F	79	MZL	Yes	162 000	NS	8.4	NS	NS	NS	NS	375 mg/m2	24	43 000	NS	NS	NS	NS	NS	NS	Yes	NS	NS
14	Parajuli (2010)	1	F	73	MCL	Yes	85 000	NS	NS	NS	NS	NS	NS	NS	24	14 000	NS	NS	NS	NS	NS	NS	Yes	NS	NS
14	Parajuli (2010)	2	F	73	MCL	Yes	100 000	NS	NS	NS	NS	NS	NS	NS	24	54 000	NS	NS	NS	NS	NS	NS	NS	NS	NS
14	Parajuli (2010)	3	F	73	MCL	Yes	126 000	NS	NS	NS	NS	NS	NS	NS	24	27 000	NS	NS	NS	NS	NS	NS	NS	NS	NS
14	Parajuli (2010)	4	F	73	MCL	Yes	123 000	NS	NS	NS	NS	NS	NS	NS	24	49 000	NS	NS	NS	NS	NS	NS	NS	NS	NS
14	Parajuli (2010)	5	F	73	MCL	Yes	103 000	NS	NS	NS	NS	NS	NS	NS	24	27 000	NS	NS	NS	NS	NS	NS	NS	NS	NS
15	Pilorge (2010)	2	M	50	WM	No	144 000	3800	11.8	NS	380	PR=92%	347	375 mg/m2	2	48 000	NS	11.4	110 400 ng/L	50	PR=50%	NS	Yes	Yes	NS
16	Novak (2012)	1	M	70	WM	NS	171 000	2900	8.4	420 ng/mL	290	1.31	NS	375 mg/m2	4	30 000	NS	NS	9670 ng/mL	180	1.78	NS	No	Yes	NS
17	El-Osta (2013)	1	F	66	MCL	NS	175 000	18 400	NS	NS	NS	NS	Normal	NS	3	16 000	NS	NS	NS	NS	NS	NS	NS	NS	NS
18	Sadashiv (2013)	1	F	63	MCL	Yes	133 000	9990	8.6	NS	NS	NS	NS	NS	24	5000	7640	7.4	NS	NS	NS	NS	Yes	NS	NS
18	Sadashiv (2013)	2	F	63	MCL	Yes	149 000	NS	NS	NS	NS	NS	NS	NS	24	5000	NS	NS	NS	NS	NS	NS	NS	NS	NS
19	Sadashiv (2013)	1	M	72	MCL	Yes	33 000	26 260	9.4	NS	NS	NS	NS	NS	24	10 000	5730	9.1	NS	NS	NS	NS	No	NS	NS
20	Sadashiv (2013)	1	M	60	MCL	Yes	146 000	12 320	10.1	NS	NS	NS	NS	NS	72	74 000	3860	8.8	NS	NS	NS	NS	NS	NS	NS
21	Sadashiv (2013)	1	F	64	MCL	Yes	91 000	13 070	8.6	NS	NS	NS	NS	NS	24	3000	6180	8.5	NS	NS	NS	NS	Yes	NS	NS
22	Sadashiv (2013)	1	M	76	MCL	Yes	122 000	20 440	14.1	NS	NS	NS	NS	NS	24	26 000	8810	13.4	NS	NS	NS	NS	Yes	NS	NS

2×ULN, two times upper limit of normal; 2×up, twofold increase; ADR, adverse reactions in hours; BV, Blastoid variant; CRS, cytokine-release syndrome; F, female; fib, fibrinogen; G, gender; Hb, haemoglobin; HCL, hairy cell leukaemia; INR, international normalised ratio; LDH, lactate dehydrogenase; LPL, lymphoplasmacytoid lymphoma; M, male; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NS, not specified; PLL, prolymphocytic leukaemia; PR, Prothrombin ratio; Pt#, Patient number; WM, Waldenstrom's macroglobulinemia.